Back to Search
NILOFER AZAD, MD
MD
Medical Oncology Physician
NPI: 1568635712Individual
Education
BAYLOR COLLEGE OF MEDICINE
Class of 2001
Research & Publications (20)
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
PMID 18669456·J Clin Oncol·2008
3-trial
Nitric oxide-mediated bcl-2 stabilization potentiates malignant transformation of human lung epithelial cells.
PMID 19556603·Am J Respir Cell Mol Biol·2010
8-other
Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production.
PMID 19520917·Am J Respir Cell Mol Biol·2010
8-other
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
PMID 19228742·Clin Cancer Res·2009
8-other
Methods to analyze S-nitrosylation of proteins involved in apoptosis.
PMID 19609753·Methods Mol Biol·2009
7-preclinical
Dependence of reactive oxygen species and FLICE inhibitory protein on lipofectamine-induced apoptosis in human lung epithelial cells.
PMID 18354056·J Pharmacol Exp Ther·2008
8-other
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
PMID 18300236·Cancer·2008
3-trial
The Fas death signaling pathway connecting reactive oxygen species generation and FLICE inhibitory protein down-regulation.
PMID 18292530·J Immunol·2008
7-preclinical
Lessons learned from a multidisciplinary heart failure clinic for older women: a randomised controlled trial.
PMID 18285347·Age Ageing·2008
2-rct
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-9441
Quick Facts
- NPI
- 1568635712
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Years in Practice
- 25
- Publications
- 20
Are you this provider?
Claim Your Profile